Does Belzutifan Plus Pembrolizumab Stop Kidney Cancer?

The management of clear-cell renal-cell carcinoma (ccRCC) is undergoing a rapid evolution. Specifically, the combination of adjuvant pembrolizumab plus belzutifan has emerged as a groundbreaking regimen for patients with resected ccRCC. Doctors face a constant challenge with high-risk patients who often experience disease recurrence after nephrectomy. Consequently, researchers have searched for therapeutic options to improve disease-free survival. The phase 3 LITESPARK-022 trial addressed this need by combining immunotherapy with a novel targeted inhibitor.

The Phase 3 LITESPARK-022 Trial Design

This randomized, double-blind trial evaluated 1,841 participants with resected ccRCC at increased risk of recurrence. Specifically, investigators assigned patients in a 1:1 ratio to receive either the combination therapy or a placebo. Patients in both cohorts received standard intravenous pembrolizumab at 400 mg every six weeks. Additionally, the experimental group took daily oral belzutifan at a dose of 120 mg. In contrast, the control group took a matching placebo daily. This intervention continued for up to one year or until disease recurrence. The primary endpoint was investigator-assessed disease-free survival, while secondary outcomes included overall survival and safety.

Benefits of Adjuvant Pembrolizumab Plus Belzutifan

The addition of belzutifan to standard immunotherapy showed remarkable clinical efficacy during the first interim analysis. Specifically, the combination treatment significantly reduced the risk of recurrence or death by 28%. The hazard ratio for disease recurrence or death was 0.72. Moreover, the estimated 24-month disease-free survival rate was 81% for the combination group. Conversely, the placebo group demonstrated a lower 24-month survival rate of 74%. Therefore, these findings support the combination as a potent option for high-risk patients. However, the overall survival data remain immature at this stage of the study.

Clinical Safety and Implications for Indian Doctors

Oncologists must carefully monitor the unique safety profiles of these combined agents. For example, belzutifan frequently causes anemia and hypoxia due to its specific mechanism of action. Consequently, clinicians must check hemoglobin levels and oxygen saturation regularly during treatment. Furthermore, pembrolizumab can trigger classic immune-related adverse events. Thus, managing these distinct toxicities requires close collaborative care. For Indian oncologists, this combination represents a significant advancement in preventing disease recurrence. Although the regimen increases treatment complexity, the survival benefit provides strong clinical justification.

Frequently Asked Questions

Q1: What are the main side effects associated with belzutifan?

Specifically, belzutifan can cause unique side effects such as anemia and hypoxia. This occurs because the drug acts as a hypoxia-inducible factor 2α inhibitor, which affects red blood cell production.

Q2: How much does adjuvant pembrolizumab plus belzutifan reduce the risk of kidney cancer recurrence?

Specifically, the combination therapy reduces the risk of disease recurrence or death by 28% compared to pembrolizumab alone. This finding is supported by a hazard ratio of 0.72.

Q3: What was the duration of treatment in the LITESPARK-022 trial?

Consequently, patients in the trial received the treatment regimen for up to one year, or until they experienced cancer recurrence.

References

1. Choueiri TK et al. Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. N Engl J Med. 2026 Jul 02. doi: 10.1056/NEJMoa2518245. PMID: 42384869.
2. Choueiri TK et al. Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study. J Clin Oncol. 2026;44(6_suppl):LBA418.
3. US Food and Drug Administration. FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma. FDA Announcement, June 2026.